Sanofi-Aventis Merger Clears Hurdle: Pfizer To Buy Aventis' Camptosar Rights For $620 Mil.

Aventis sells irinotecan primarily in Europe, Asia and Africa, and recorded sales of $320 mil. in 2003. Camptosar directly competes with Sanofi's Eloxatin in the colorectal cancer market.